We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $588M
1-Year Est. Return 182.75%
This Fund
S&P 500
This Quarter Est. Return
+6.92%
1 Year Est. Return
+182.75%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$588M
AUM Growth
+$7.2M
Cap. Flow
-$2.16M
Cap. Flow %
-0.37%
Top 10 Hldgs %
36.51%
Holding
220
New
75
Increased
41
Reduced
27
Closed
76

Top Buys

1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$9.57M
2
UTHR icon
United Therapeutics
UTHR
+$8.62M
3
INCY icon
Incyte
INCY
+$7.79M
4
COGT icon
Cogent Biosciences
COGT
+$7.05M
5
VKTX icon
Viking Therapeutics
VKTX
+$6.05M

Top Sells

1
REGN icon
Regeneron Pharmaceuticals
REGN
+$7.95M
2
TERN
Terns Pharmaceuticals
TERN
+$6.74M
3
ANIP icon
ANI Pharmaceuticals
ANIP
+$4.21M
4
BIOA
BioAge Labs
BIOA
+$4.07M
5
CORT icon
Corcept Therapeutics
CORT
+$3.27M

Sector Composition

1 Healthcare 38.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LGND icon
176
Ligand Pharmaceuticals
LGND
$5.94B
– –
-2,987
Closed -$565K
LQDA icon
177
Liquidia Corp
LQDA
$6.69B
– –
-21,881
Closed -$812K
MLTX icon
178
CALL
MoonLake Immunotherapeutics
MLTX
$1.59B
– –
-47,200
Closed -$622K
MNKD icon
179
CALL
MannKind Corp
MNKD
$1.25B
– –
-552,300
Closed -$3.13M
MREO
180
CALL
Mereo BioPharma
MREO
$51.5M
– –
-1,999,500
Closed -$833K
NTLA icon
181
PUT
Intellia Therapeutics
NTLA
$1.66B
– –
-316,900
Closed -$2.85M
OCUL icon
182
CALL
Ocular Therapeutix
OCUL
$2.01B
– –
-545,200
Closed -$6.62M
PALI icon
183
Palisade Bio
PALI
$328M
– –
-166,049
Closed -$390K
PBYI icon
184
CALL
Puma Biotechnology
PBYI
$428M
– –
-33,800
Closed -$201K
PCRX icon
185
Pacira BioSciences
PCRX
$1.01B
– –
-48,025
Closed -$1.24M
PLRX icon
186
Pliant Therapeutics
PLRX
$68.7M
– –
-144,914
Closed -$177K
PRAX icon
187
PUT
Praxis Precision Medicines
PRAX
$8.59B
– –
-100,600
Closed -$29.7M
PRTA icon
188
Prothena Corp
PRTA
$443M
– –
-106,539
Closed -$1.02M
PTGX icon
189
Protagonist Therapeutics
PTGX
$8.49B
– –
-22,700
Closed -$1.98M
QQQ icon
190
PUT
Invesco QQQ Trust
QQQ
$466B
– –
-30,000
Closed -$18.4M
RARE icon
191
CALL
Ultragenyx Pharmaceutical
RARE
$2.98B
– –
-100,000
Closed -$2.3M
REGN icon
192
CALL
Regeneron Pharmaceuticals
REGN
$71.2B
– –
-5,000
Closed -$3.86M
REGN icon
193
Regeneron Pharmaceuticals
REGN
$71.2B
– –
-10,300
Closed -$7.95M
RIGL icon
194
Rigel Pharmaceuticals
RIGL
$771M
– –
-30,000
Closed -$1.28M
RNAM
195
CALL
DELISTED
Avidity Biosciences
RNAM
– –
-328,000
Closed -$23.7M
RVPH
196
CALL
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
– –
-25,000
Closed -$140K
RXRX icon
197
CALL
Recursion Pharmaceuticals
RXRX
$1.6B
– –
-741,900
Closed -$3.03M
FLNA
198
PUT
Filana Therapeutics
FLNA
$52.2M
– –
-10,600
Closed -$21K
SLNO
199
CALL
DELISTED
Soleno Therapeutics
SLNO
– –
-53,100
Closed -$2.46M
SLNO
200
DELISTED
Soleno Therapeutics
SLNO
– –
-26,892
Closed -$1.25M
5 6 7
8
9

Similar funds

MC
Martin & Co Knoxville, Tennessee $587M AUM 16.39% 1-Year Est. Return
BCM
Blume Capital Management Berkeley, California $588M AUM 29.16% 1-Year Est. Return
PFG
Premier Financial Group Eureka, California $587M AUM 21.88% 1-Year Est. Return
FMI
Frec Markets Inc San Francisco, California $587M AUM
BMWS
Brady Martz Wealth Solutions Grand Forks, North Dakota $587M AUM 17.88% 1-Year Est. Return
EGWAG
Elwood & Goetz Wealth Advisory Group Athens, Georgia $589M AUM 19.26% 1-Year Est. Return
PFG
PAX Financial Group San Antonio, Texas $586M AUM 15.84% 1-Year Est. Return
GIM
Garden Investment Management Greenwich, Connecticut $586M AUM 15.35% 1-Year Est. Return

Diadema Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Diadema Partners held 220 positions worth $588M, up 1.2% from $581M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Diadema Partners's Q1 2026 filing shows 75 new, 41 increased, 27 reduced and 76 closed positions. Its largest new stake was Jazz Pharmaceuticals: 54,755 shares worth $10.4M. The largest sale was Regeneron Pharmaceuticals, an estimated $7.95M.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 29% a quarter earlier.

  • Diadema Partners's largest Q1 2026 buy was Jazz Pharmaceuticals: 54,755 shares worth $10.4M.
  • Diadema Partners added most to United Therapeutics in Q1 2026, an estimated $8.62M increase.
  • Diadema Partners's biggest Q1 2026 reduction was Terns Pharmaceuticals, cutting an estimated $6.74M.
  • Diadema Partners fully exited Regeneron Pharmaceuticals in Q1 2026, selling an estimated $7.95M.
  • Diadema Partners's ten largest holdings make up 37% of its $588M portfolio in Q1 2026.
  • Diadema Partners opened 75 new positions and closed 76 in Q1 2026.
  • Diadema Partners's portfolio value rose 1.2% quarter-over-quarter to $588M.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.